Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 25, Issue 3, 2003, Pages 225-248

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1311 LIPIODOL; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 5 ETHYNYLURACIL; 5A8; AGOMELATINE; ALEFACEPT; ALMOTRIPTAN; ANALGESIC AGENT; ANTIALLERGIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ATOMOXETINE; AZIMILIDE; BERTILIMUMAB; BICIFADINE; CANNABIDIOL; CARDIOVASCULAR AGENT; CASPOFUNGIN; CGP 51901; CICLESONIDE; CIPAMFYLLINE; DARUNAVIR; DENUFOSOL; DESLORATADINE; DIBOTERMIN ALPHA; EFALIZUMAB; ELETRIPTAN; EPI KAL2; HRG214; HSPPC 96; LAS 34475; LY 450108; MBI 594AN; NC 100100; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROVENGE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHOP 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL PHARMACOLOGY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; INTERNET; MEDICAL LITERATURE; MEDICAL SOCIETY; REVIEW; SIDE EFFECT;

DOUBLE-BLIND METHOD; DRUG THERAPY; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0037986434     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Serebruany, V.L., Malinin, A.I., O'Connor, C.M., Gurbel, P.A. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease: For the Roxifiban Oral Compound Kinetics Evaluation Trial-I (the ROCKET-I platelet substudy). Circulation 2002, 106 (19, Suppl. 2): Abst 2436.
2. Dyke, C.K. et al. First experience with direct factor Xa inhibition in patients with stable coronary disease. A pharmacokinetic and pharmacodynamic evaluation. Circulation 2002, 105(20): 2385.
3. Abizaid, A., Ormiston, J., Sousa, J.E. et al. First in man experience with mycophenolic acid-eluting Duraflex stent to treat de novo native coronary stenosis: Early results from the IMPACT trial. Circulation 2002, 106 (19, Suppl. 2): Abst 1783.
4. Pratt, C.M., Singh, S.N., Al-Khalidi, H. et al. Efficacy of azimilide in treatment of atrial fibrillation in a high-risk post-myocardial infarction population. Circulation 2002, 106 (19, Suppl. 2): Abst 3128.
5. Solomon, S.D., Skali, H., Bourgoun, M. et al. Improvement in ventricular size and function following one-year treatment with ACE or vasopeptidase inhibition in patients with heart failure: The OVERTURE echo study. Circulation 2002, 106 (19, Suppl. 2): Abst 2524.
6. Rousseau, M.F., Ahn, S.A., Van Mieghem, W., Limburg, H., Pouleur, H.G. Neurohormonal changes during enalapril or omapatrilat therapy for congestive heart failure: An OVERTURE substudy. Circulation 2002, 106 (19, Suppl. 2): Abst 3377.
7. Lederman, R.J., Mendelsohn, R., Anderson, R.D. et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 2002, 359: 2053.
8. Malacco, E. et al. Dose-response relationship of zofenopril in essential hypertension - A 24-hour blood pressure-monitoring study. Clin Drug Invest 2002, 22(1): 9.
9. Barst, R.J., Rich, S., Widlitz, A., Horn, E.M., McLaughlin, V., McFarlin, J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: Open-label pilot study. Chest 2002, 121(6): 1860.
10. Sorenson, A.G. Results of a multi-center phase 3 trial of magnetic resonance angiography with MS-325, a blood pool contrast agent, for the detection of peripheral vascular disease in the aortoiliac region. Eur Congr Radiol (March 7, 2003, Vienna) 2003: Abst B-0020.
11. Williams, T., Cicardi, M., Bork, K., Gonzalez-Quevedo, T., Caballero, T. DX-88, a recombinant inhibitor of human plasma kallikrein. Evaluation of efficacy and safety in patients with hereditary angioedema. 60th Annu Meet Am Acad Allergy Asthma Immunol (March 7, 2003, Denver) 2003: Abst L-3.
12. Gagné, C. et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105(21): 2469.
13. Rutgeerts, P., Lemmens, L., Van Assche, G., Noman, M., Borghini-Fuhrer, I., Goedkoop, R. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): Results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003, 17(2): 185.
14. Desjardins, P., Link, A., Daniels, S., Baum, D., Pintos, M., Musoles, S. Comparison of LAS 344475 and rofecoxib in acute post-impaction dental pain. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 860.
15. Czobor, P., Stark, J., Beer, G. et al. A double-blind, placebo controlled randomized study of DOV220,075 (bicifadine) SR and codeine 60 mg in the treatment of post-operative dental pain. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 915.
16. Goncales, F. et al. Peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin in chronic hepatitis C: Retreatment of patients who relapsed virologically after 24 weeks of therapy. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 794.
17. Diago, M. et al. Optimized virological response in genotype 4 chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) (Pegasys®) in combination with ribavirin (RBV). 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 804.
18. McCleane, G., Rauschkolb, C. An open label trial to assess the efficacy and safety of ascending doses of SPM 927 in subjects with chronic refractory neuropathic pain. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 880.
19. Desjardins, P.J., Shu, V.S., Recker, D.P., Verburg, K.M., Woolf, C.J. A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology 2002, 97(3): 565.
20. Leung, D.Y.M., Sampson, H.A., Yunginger, J.W., Burks, W., Schneider, L.C., Shanahan, W. Effect of anti-IgE therapy (TNX-901) in patients with severe peanut allergy. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 826.
21. Flood-Page, P., Phipps, S., Menzies-Gow, A., Ong, Y., Kay, A.B. Effect of intravenous administration of an anti-IL-5 mAb (mepolizumab) on allergen-induced tissue eosinophilia, the late-phase allergic reaction and the expression of a marker of repair/remodeling in human atopic subjects. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 774.
22. Bousquet, J., Harnest, U., Chung, K.F., Oshinyemi, K., Blogg, M. Omalizumab improves symptom control in patients with poorly controlled allergic asthma and concomitant rhinitis. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 295.
23. Boesel, K.M., Griffith, D.T., Prussin, C., Foster, B., Lin, H., Casale, T.B. Rapid reduction of basophil FcεRl expression by omalizumab. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 787.
24. Griffith, D.T., Boesel, K.M., Prussin, C., Foster, B., Lin, H., Casale, T.B. Dendritic cell FCεRl expression is rapidly down-regulated with omalizumab. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 784.
25. Lin, H., Romero, F.A., Boesel, K.M., Griffith, D.T., Casale, T.B. Omalizumab rapidly inhibits nasal allergic responses. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 1118.
26. Ishikawa, T., Ogino, S., Nagakura, T., Okubo, K. Clinical efficacy of omalizumab on seasonal allergic rhinitis associated with Japanese cedar pollen. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 54.
27. Schaberg, A.E., Meltzer, E.O., LaForce, C.F. et al. INS37217 intranasal, a P2Y2 receptor agonist, is a novel treatment for allergic rhinitis. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 16.
28. Pereira, S., Clark, T., Yarby, Y. et al. Effects of anti-eotaxin monoclonal antibody CAT-213 on allergen-induced rhinitis. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 801.
29. Prussin, C., James, S.P., Huber, M.M., Klion, A.D., Metcalfe, D.D. Pilot study of anti-IL-5 in eosinophilic gastroenteritis. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 827.
30. Grysczyk, H. et al. Antimycotic treatment of pulmonary aspergilloma in patients without neutropenia. Dtsch Med Wochenschr 2002, 127(10): 492.
31. Fried, M.W., Shiffman, M.L., Reddy, K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002, 347(13): 975.
32. Jeffers, L.J. et al. Peginterferon alfa-2a (40KD) (Pegasys®) in combination with ribavirin in African American and Caucasian patients with HCV genotype 1: An interim report of a comparative, multicenter; efficacy and safety study. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 784.
33. Bronowicki, J.-P. et al. Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2a (40KD) (Pegasys) alone versus peginterferon alfa-2a plus ribavirin in naive patients with chronic hepatitis C and genotype 1 who respond to a 24 week course therapy of peginterferon alfa-2a plus ribavirin: Preliminary results of an open-multicenter, randomized trial. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 520.
34. Herrine, S.K. et al. Efficacy and safety of peginterferon alfa-2a (Pegasys®) combination therapies in patients who relapsed on Rebetron™ therapy. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 781.
35. Poynard, T. et al. The effect of treatment with pegylated interferon alfa-2b and ribavirin on hepatic steatosis in patients infected with hepatitis C virus genotype 3. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 483.
36. Gross, J.B. et al. Interim results in the RENEW trial: A dose comparison study of high-dose peginterferon alfa-2b and ribavirin for interferon/ribavirin non-responders with chronic hepatitis C. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 783.
37. Jacobson, I. et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 782.
38. Portal, I. et al. Treatment with pegylated-interferon alpha-2b (PEG-interferon) + ribavirin in relapsers to standard interferon + ribavirin in chronic hepatitis C: Efficacy and safety results from a randomized multicentric French study. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 785.
39. Esmat, G. et al. Treatment with PEG-interferon alfa-2b (PEGIFN) plus ribavirin compared to interferon alfa-2b (IFN alfa-2b) plus ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 803.
40. Krawitt, E.L. et al. Efficacy of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C previously unresponsive to interferon-based therapy. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 786.
41. Chousterman, M. et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C non responders to interferon monotherapy or standard combination therapy. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 798.
42. Hor, R. et al. Concomitant ddl/d4T and interferon (standard or pegylated IFN)/ribavirin treatments may induce high risk of mitochondrial toxicity in HIV/HCV co-infected patients (ANRS HC-02-RIBAVIC study). 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 481.
43. Perronne, C. et al. ANRS HC02-RIBAVIC: A randomized controlled trial of pegylated-interferonA-2b plus ribavirin vs interferonA-2b plus ribavirin as primary treatment of chronic hepatitis C HIV co-infected patients. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 480.
44. Romero, M. et al. Therapy with pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 801.
45. Woods, G., Teppler, H., Isaacs, R., Friedland, I., Jonas, L., Gesser, R. Ertapenem (ETP) 1 g once a day has an excellent safety profile in the elderly. 40th Annu Meet Infect Dis Soc Am (Oct 24, 2002, Chicago) 2002: Abst 613.
46. Mora-Duarte, J., Betts, R., Rotstein, C. et al. Caspofungin (CAS) vs. amphotericin B deoxycholate (AmB) in the treatment of candidemia: Results from a multi-center, randomized, double-blind study. 40th Annu Meet Infect Dis Soc Am (Oct 24, 2002, Chicago) 2002: Abst 13.
47. Forrest, G., Kleinberg, M., Chan, S. Outcomes of caspofungin therapy and the neutropenic host in a university cancer center. 40th Annu Meet Infect Dis Soc Am (Oct 24, 2002, Chicago) 2002: Abst 354.
48. Dezube, B.J., Proper, J., Zhang, J.L. et al. A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: A phase 1 study. J Infect Dis 2003, 187(3): 500.
49. Kuritzkes, D.R., Jacobson, J.M., Powderly, W. et al. Safety and preliminary anti-HIV activity of an anti-CD4 mAb (TNX-355; formerly Hu5A8) in HIV-infected patients. 10th Conf Retroviruses Opportunistic Infect (Feb 10, 2003, Boston) 2003: Abst 13.
50. Murphy, R. et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-Week results of BMS study 008/044. 10th Conf Retroviruses Opportunistic Infect (Feb 10, 2003, Boston) 2003: Abst 555.
51. Schooley, R.T. et al. Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study. AIDS 2002, 16(9): 1257.
52. Cooper, D., Hall, D., Jayawcera, D. et al. Baseline phenotypic susceptibility to lipranavir/ritonavir is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.521). 10th Conf Retroviruses Opportunistic Infect (Feb 10, 2003, Boston) 2003: Abst 596.
53. Bandera, A., Gori, A., Trabattoni, D. et al. Positive immunomodulatory effects of tucaresol in HIV-infected patients: Results from a phase I/II trial after 40 weeks of follow-up. 10th Conf Retroviruses Opportunistic Infect (Feb 10, 2003, Boston) 2003: Abst 654.
54. Kutler, C., Koll, B., Raucher, B., Saltzman, B. Treatment of resistant oral and esophageal candidiasis with caspofungin in patients with AIDS. 40th Annu Meet Infect Dis Soc Am (Oct 24, 2002, Chicago) 2002: Abst 355.
55. Sanne, I., Piliero, P., Squires, K., Thiry, A., Schnittman, S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A doseranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003, 32(1): 18-29.
56. Nadler, J., Rodriguez-French, A., Millard, J., Wannamaker, P. The NEAT study: GW433908 efficacy and safety in ART-naive subjects, final 48-week analysis. 10th Conf Retroviruses Opportunistic Infect (Feb 10, 2003, Boston) 2003: Abst 177.
57. Macmanus, S., Yates, P., White, S., Richards, N., Snowden, W. GW433908 in ART-naive subjects: Absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen. 10th Conf Retroviruses Opportunistic Infect (Feb 10, 2003, Boston) 2003: Abst 598.
58. DeJesus, E., LaMarca, A., Sension, M., Beltran, C., Yeni, P. The Context study: Efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). 10th Conf Retroviruses Opportunistic Infect (Feb 10, 2003, Boston) 2003: Abst 178.
59. Schugt, I., Kreuter, A., Schlottmann, R., Bader, A., Altmeyer, P., Brockmeyer, N.H. Pegylated interferon alfa-2b: A new therapeutic option in the treatment of early-stage HIV infection. 10th Conf Retroviruses Opportunistic Infect (Feb 10, 2003, Boston) 2003: Abst 59.
60. Arasteh, K., Clumeck, N., Pozniak, A. et al. First clinical results on antiretroviral activity, pharmacokinetics, and safety of TMC114, an HIV-1 protease inhibitor, in multiple PI-experienced patients. 10th Conf Retroviruses Opportunistic Infect (Feb 10, 2003, Boston) 2003: Abst 8.
61. Ortiz-Ruiz, G. et al. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002, 34(8): 1076.
62. Petermann, W., Lavin, B., Patel, M. Efficacy of telithromycin (800mg qd) vs comparators in patients with community-acquired pneumonia and bacteremia. 40th Annu Meet Infect Dis Soc Am (Oct 24, 2002, Chicago) 2002: Abst 42.
63. Hayden, F.G., Coats, T., Kim, K. et al. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: Efficacy and tolerability in phase II clinical trials. Antivir Ther 2002, 7(1): 53.
64. Moise, P.A., Forrest, A., Birmingham, M.C., Schentag, J.J. The efficacy and safety of linezolid as treatment for Staphylococcus aureas injections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002, 50(6): 1017.
65. Molina, J.-M., Tourneur, M., Sarfati, C. et al. Fumagillin treatment of intestinal microsporidiosis. New Engl J Med 2002, 346(25): 1963.
66. Tomera, K.M., Burdmann, E.A., Pamo Reyna, O.G. et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: Results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother 2002, 46(9): 2895.
67. Schumacher, H.R., Boice, J.A., Daikh, D.I. et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ - Br Med J 2002, 324(7352): 1488.
68. Brown, W.V., Bays, H.E., Hassman, D.R. et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J 2002, 144(6): 1036.
69. Schneck, D.W., Knopp, R.H., Ballantyne, C.M., McPherson, R., Chitra, R.R., Simonson, S.G. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003, 91(1): 33.
70. Petri, M.A., Lahita, R.G., van Vollenhoven, R.F. et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2002, 46(7): 1820.
71. Reginster, J.Y., Spector, T., Badurski, J. et al. A short-term run-in study can significantly contribute to increasing the quality of longterm osteoporosis trials. The strontium ranelate phase 3 program. Osteoporosis Int 2002, 13 (Suppl. 1): Abst P85MO.
72. Reginster, J.-Y., Meunier, P.J. Incidence ofosteoporotic non vertebral fractures coming in the strontium ranelate run-in study could validate sample size calculation. Osteoporosis Int 2002, 13 (Suppl. 3): Abst P71.
73. Reginster, J.-Y., Diez-Perez, A., Ortolani, S., Pors-Nielsen, S., Meunier, P.J. Supplementation of calcium-vitamin D should be adapted according to the patients status in international phase 3 program on osteoporosis. Osteoporosis Int 2002, 13 (Suppl. 3): Abst P69.
74. Meunier, P.J., Reginster, J.Y. Dose-related bone effects of strontium ranelate in postmenopausal women. Osteoporosis Int 2002, 13 (Suppl. 1): Abst SY9.
75. Reginster, J.-Y., Sawicki, A., Devogelaer, J.P. et al. Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis. Osteoporosis Int 2002, 13 (Suppl. 3): Abst O14.
76. Meunier, P.J., Roux, C., Ortolani, S. et al. Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. IOF World Congr Osteoporos (May 10, 2002, Lisbon) 2002: Abst O45.
77. Meunier, P.J., Lorenc, R.S., Smith, I.G. et al. Strontium ranelate: New efficient anti-osteoporotic agent for treatment of vertebral osteoporosis in postmenopausal women. Osteoporosis Int 2002, 13 (Suppl. 3): Abst P66.
78. Marquis, P., De la Loge, C., Roux, C., Meunier, P.J., Reginster, J.Y. Strontium ranelote treatment prevents health-related quality of life impairment in postmenopausal women with severe osteoporosis: Results from the SOT1 study. Osteoporosis Int 2002, 13 (Suppl. 3): Abst O5.
79. Gottesdiener, K., Schnitzer, T., Fisher, C. et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002, 41(9): 1052.
80. Sikes, D.H., Agrawal, N.M., Zhao, W.W., Kent, J.D., Recker, D.P., Verbug, K.M. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002, 14(10): 1101.
81. Leung, A.T., Malmstrom, K., Gallacher, A.E. et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002, 18(2): 49.
82. Cohen, S., Hurd, E., Cush, J. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-I receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46(3): 614.
83. Nuki, G., Bresnihan, B., Bear, M.B., McCabe, D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-I receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46(11): 2838.
84. Collantes, E., Curtis, S.P., Lee, K.W. et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25I42273]. BMC Fam Pract 2002, 3(1): 10.
85. Elkayam, O., Caspi, D., Paran, D. et al. Effect of anti-TNFα therapies on the immunogenicity of pneumococcal vaccination in patients with rheumatic diseases. 66th Annu Meet Am Coll Rheumatol (Oct 25, 2002, New Orleans) 2002: Abst 861.
86. Bensen, W., Weaver, A., Espinoza, L. et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: A randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford) 2002, 41(9): 1008.
87. Hashimoto, T., Shigenobu, K., Yamane, S. Radiographic assessment and surgical exploration of instrumented posterolateral lumbar fusion using osteogenic protein-I (rhBMP-7). 70th Annu Meet Am Acad Orthop Surg (Feb 5, 2003, New Orleans) 2003: Abst P324.
88. Hilibrand, A.S., Patel, T.C., Vaccaro, A. et al. One year follow up on patients in a pilot safety and efficacy study of OP-I (rhBMP-7) in posterolateral lumbar fusion as a replacement for iliac crest autograft. 70th Annu Meet Am Acad Orthop Surg (Feb 5, 2003, New Orleans) 2003: Abst 161.
89. Boden, S.D., Kang, J., Sandhu, H., Heller, J.G. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: A prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 2002, 27(23): 2662.
90. Stromqvist, B., Aspenberg, P. Randomized radiostereometric study comparing osteogenic protein-I (bone morphogenetic protein-7) and autograft bone in human noninstrumented posterolateral lumbar fusions. 70th Annu Meet Am Acad Orthop Surg (Feb 5, 2003, New Orleans) 2003: Abst P292.
91. Eriksson, B.I., Bergqvist, D., Kälebo, P. et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO II randomised trial. Lancet 2002, 360(9344): 1441.
92. Camu, F., Beecher, T., Recker, D.P., Verburg, K.M. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002, 9(1): 43.
93. Casati, A. et al. A double-blinded, randomized comparison of either 0.5% levobupivacaine or 0.5% ropivacaine for sciatic nerve block. Anesth Analg 2002, 94(4): 987.
94. Vansteenkiste, J. et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002, 94(16): 1211.
95. Green, M.D., Koelbl, H., Baselga, J. et al. A randomized doubleblind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003, 14(1): 29.
96. Awada, A., Eskens, F.A.L.M., Piccart, M. et al. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer 2002, 38(17): 2272.
97. Rubin, E.H., de Alwis, D.P., Pouliquen, I. et al. A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar. 3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 2002, 8(12): 3710.
98. Cohen, L., de Moor, C., Parker, P.A., Amato, R.J. Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine. Urol Oncol 2002, 7(3): 119.
99. Lencioni, R., Cioni, D., Bruix, J., Majno, P., Bartolozzi, C. SHU555A-enhanced-MRI vs spiral CT: Clinical impact factor in the management of liver malignancies. Eur Congr Radiol (March 7, 2003, Vienna) 2003: Abst B-0649.
100. Kirsch, M., Zinke, A., Bock, P., Albrecht, L., Weigel, C., Hosten, N. I-131 Lipiodol therapy in liver neoplasms: First results. Eur Congr Radiol (March 7, 2003, Vienna) 2003: Abst B-0800.
101. Sidhu, P.S., Leen, E., Correas, J.-M., Needleman, L., Cosgrove, D.O., Robbin, M. Multi-centre study of Sonazoid enhanced ultrasound of patients with known primary cancer: Improved detection of liver metastases. Eur Congr Radiol (March 7, 2003, Vienna) 2003: Abst B-0252.
102. Rothenberg, M.L. et al. Phase 11 trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: A Southwest Oncology Group study. Ann Oncol 2002, 13(10): 1576.
103. Laus, R., Small, E., Schellhammer, P.F. et al. Dendritic cells pulsed with prostatic acid phosphatase-GM-CSF (APC-8015) for immunotherapy of hormone refractory prostate cancer: A phase III randomized, double blind, placebo controlled trial. 7th Int Symp Dendritic Cells (Sept 19, 2002, Bamberg) 2002: Abst P152.
104. Miller, K., Raabe, N., Trachtenberg, J. et al. ZDI839 ('Iressa'), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is well tolerated in combination with mitoxantrone and prednisone in patients with hormonerefractory prostate cancer (HRPC). BJU Int 2002, 90 (Suppl. 2): Abst P-5.1.02.
105. Wilding, G., Small, E., Soulie, P., Trump, D., Das-Gupta, A. A pilot trial of ZDI839 ('Iressa'), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with docetaxel and estramustine in patients with hormone-refractory prostate cancer (HRPC). BJU Int 2002, 90 (Suppl. 2): Abst P-5.1.03.
106. Cortes, J., Holyoake, T.L., Silver, R.T. et al. Continuous oral lonafarnib (Sarasar™) for the treatment of patients with advanced hematologic malignancies: A phase II study. Blood 2002, 100 (11, Part I): Abst 3132.
107. Larson, R.A. et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002, 16(9): 1627.
108. Gerrard, G., Ganeshaguru, K., Baker, R. et al. Premilinary pharmacodynamic analysis on a phase I study of the P-gp inhibitor zosuquidar (LY335979) given by short intravenous infusion in combination with daunorubicin and cytarabine in AML patients. 7th Congr Eur Haematol Assoc (June 6, 2002, Florence) 2002: Abst 0566.
109. Fischer, T. et al. Safety and efficacy of ST1-571 (Imatinib mesylate in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Leukemia 2002, 16(7): 1220.
110. Davies, A.J., Redford, J.A., Rohatiner, A.Z.S. et al. Durable remissions may be achieved with tositumomab and I131 tositumomab in recurrent and refractory B cell lymphoma. Leukemia 2003, 17(3): Abst 036.
111. Refern, C., Guthrie, T.H., Smith, M.R. et al. A phase II trial of Favid™ [Id-KLH] for relapsed indolent non-Hodgkin's lymphoma. Blood 2002, 100 (11, Part 1): Abst 1383.
112. Gerrard, G., Ganeshaguru, G., Payne, B. et al. Inhibition of P-gp activity in AML patients treated with zosuquidar trihydrochloride. Leukemia 2003, 17(3): Abst O29.
113. Estey, E.H., Giles, F.J., Beran, M. et al. Experience with gemtuzumab ozogamycin ("Mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002, 99(11): 4222.
114. Cardinali, D.P., Brusco, L.I., Liberczuk, C., Furio, A.M. The use of melatonin in Alzheimer's disease. Neuroendocrinol Lett 2002, 23 (Suppl. 1): 20.
115. Mathew, N.T. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. Headache 2002, 42(1): 32.
116. Cady, R. Almotriptan reduces the incidence of migrain-associated symptoms: A pooled analysis. Headache 2002, 42 (Suppl. 1): S26.
117. Sandrini, G., Färkkilä, M., Burgess, G., Forster, E., Haughie, S. Eletriptan vs samatriptan: A double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002, 59(8): 1210.
118. Killestein, J., Hoogervorst, E.L.J., Reif, M. et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002, 58(9): 1404.
119. Djaldetti, R., Inzelberg, R., Giladi, N. et al. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord 2002, 17(2): 297.
120. Dowling, G.A., Aminoff, M.J., Mastick, J., Colling, E., Carter, J.H., Singer, C.M. The effect of melatonin treatment on sleep and sleepiness in dopamine agonist treated patients with Parkinson's disease. Mov Disord 2002, 17 (Suppl. 5): Abst P297.
121. Schwid, S.R. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2002, 17 (Suppl. 5): Abst P263.
122. Bushara, K.O., Shill, H.S., Hallett, M. Octanol for essential tremor. A double-blind, placebo-controlled trial. Mov Disord 2002, 17 (Suppl. 5): Abst P1164.
123. Shill, H.A., Reich, M., Bushara, K.O., Grimes, G., Hallett, M. Dose-escalation study of oral I-actanol in patients with essential tremor. Mov Disord 2002, 17 (Suppl. 5): Abst P1151.
124. 2C receptors antagonist, in the treatment of major depressive disorders. Encephale 2002, 28(4): 356.
125. Montorsi, F., Verheyden, B., Junemann, K.-P. et al. Long-term safety experience with tadalafil. Eur Urol Suppl.2003, 2(1): Abst 373.
126. Brock, G.B., McMahon, C.G., Chen, K.K. et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002, 168(4): 1332.
127. Koutsky, L.A., Ault, K.A., Wheeler, C.M. et al. A controlled trial of a haman papillomavirus type 16 vaccine. New Engl J Med 2002, 347(21): 1645.
128. Busse, W.W., Corren, J., Lanier, B.Q., Everhard, F., Surrey, K., Kirchdoerfel, L. Omalizumab improves asthma-specific quality of life (QoL): An analysis of data from 1071 patients. J Allergy Clin Immunol 2002, 109 (1, Part 2): Abst 891.
129. Phipps, S., Flood-Page, P., Menzies-Gow, A. et al. Anti-IL-5 (mepolizumab) reduces the expression of tenascin, procollagen III and lumican in the reticular basement membrane of human atopic asthmatics. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 839.
130. Szefler, S.J., Herron, J., Lloyd, M. et al. High doses of the novel inhaled steroid ciclesonide have no effect on HPA-axis function in patients with moderate-to-severe persistent asthma. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 590.
131. LaForce, C.F., Baker, J.W., Amin, D. et al. Ciclesonide, a novel inhaled steroid, has no effect on hypothalamic-pituitary-adrenal (HPA)-axis function in mild-to-moderate asthmatics. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 596.
132. Chung, K.F., Hogate, S., O'Brien, J., Fox, H., Thirlwell, J. Inhaled corticosteroid dose-reducing effect of omalizumab in patients with controlled, severe asthma according to usage of inhaled long-acting β-agonists. J Allergy Clin Immunol 2002, 109 (1, Part 2): Abst 726.
133. Ayres, J.G., Niven, R., Ayre, G., Blogg, M., Fox, H. Omalizumab reduces the rate of asthma deterioration-related incidents in patients with poorly controlled allergic asthma. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 534.
134. Higgins, B., Britton, M., Carrillo, T., Oshinyemi, K., Blogg, M. Anti-IgE therapy with omalizumab improves asthma-related quality of life of patients with poorly controlled allergic asthma. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 299.
135. Chipps, B., Kim, K., Korenblat, P., Deniz, Y., Zheng, B., Carroll, A. Effect of omalizumab on healthcare utilization in patients with moderate to severe allergic asthma. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 301.
136. Israel, E. et al. Omalizumab does not induce thrombocytopenia in the treatment of asthma. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 310.
137. Salib, R., Salagean, M., Lau, L. et al. The anti-inflammatory response of anti-eotaxin monoclonal antibody CAT-213 on nasal allergen-induced cell infiltration and activation. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 1117.
138. Greiff, L., Persson, C.G.A., Andersson, M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol 2002, 89(4): 413.
139. Salmun, L.M., Lorber, R. 24-Hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam Pract 2002, 3(1): 14.
140. Hamelmann, E.H., Rolinck-Werninghaus C., Kopp, M., Kuehr, J., Wahn, U. Correlation of specific and total IgE serum levels with symptoms and effects of anti-IgE treatment in children with seasonal allergic rhinitis (SAR). J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 1116.
141. Friedland, D., Sharp, D., Robinson, J. Double-blind, randomized, vehicle-controlled study to assess the safety and efficacy of MBl 594AN in the treatment of acne vulgaris. 61st Annu Meet Am Acad Dermatol (March 21, 2003, San Francisco) 2003: Abst P51.
142. Kucharekova, M., Hornix, M., Ashikaga, T., T'Kint, S., Schalkwijk, J., van der Valk, P.G.M. Cipamfylline in experimentally induced skin irritation. J Eur Acad Dermatol Venereol 2002, 16 (Suppl. 1): Abst P8-12.
143. Krueger, G.G., Papp, K.A., Stough, D.B., Loven, K.H., Gulliver, W.P., Ellis, C.N. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002, 47(6): 821.
144. Koo, J.Y. Efalizumab (anti-CDIIa) is safe and well tolerated in the treatment of moderate to severe plaque psoriasis: Pooled results of two phase III clinical trials. 60th Annu Meet Am Acad Dermatol (Feb 22, 2002, New Orleans) 2002: Abst P548.
145. Menter, A. Time to onset of improvement during efalizumab (anti-CDIIa) therapy in patients with moderate to severe plaque psoriasis. 60th Annu Meet Am Acad Dermatol (Feb 22, 2002, New Orleans) 2002: Abst P549.
146. Gottlieb, A. Subcutaneous efalizumab (anti-CDIIa) is effective in the treatment of moderate to severe plaque psoriasis: Pooled results of two phase III clinical trials. 60th Annu Meet Am Acad Dermatol (Feb 22, 2002, New Orleans) 2002: Abst P576.
147. Heil, S.H. et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002, 67(2): 149.
148. Pretorius, M., Rosenbaum, D., Vaughan, D.E., Brown, N.J. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 2003, 107(4): 579.
149. Grant, J.A., Riethuisen, J.-M., Monlaert, B., De Vos, C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: Suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002, 88(2): 190.
150. Chalon, S., Toublanc, N., Pereira, A., Zhang, L., Guillaume, M., Chappell, A. Single dose safety, tolerance, and pharmacokinetics of LY450108, an AMPA potentiator, in young healthy male subjects. Eur Neuropsychopharmacol 2002, 12 (Suppl. 3): Abst P.6.044.
151. Martin, P.D., Mitchell, P.D., Schneck, D.W. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002, 54(5): 472.
152. Emmick, J., Mitchell, M., Bedding, A. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. Eur Urol Suppl.2003, 2(1): Abst 372.